Literature DB >> 2318481

Ovarian serous borderline tumors with stromal microinvasion: a report of 21 cases.

D A Bell1, R E Scully.   

Abstract

The clinicopathologic features of 21 cases of otherwise typical serous borderline tumors that contained small foci of stromal invasion were reviewed. The mean age of the patients was 43 years and six of them were pregnant at the time of diagnosis. Nineteen tumors were stage I, one was stage III (para-aortic lymph node involvement) and one was stage IV (parenchymal liver metastasis). The tumor invaded the stroma predominantly as individual cells or nests or clusters of cells with abundant eosinophilic cytoplasm (17 cases), as small confluent nests with a cribriform pattern (two cases) and as rounded aggregates of papillae (two cases). Seven women were treated with bilateral salpingo-oophorectomy and hysterectomy; 13 had less than bilateral oophorectomy. Of the 17 patients for whom followup data were available, 16 were without evidence of disease 1 to 11 (mean, 5.2) years postoperatively, and one patient had a serous borderline tumor with microinvasion in a conserved contralateral ovary 2.8 years postoperatively, but was well 6 months after a partial oophorectomy. These data suggest that serous borderline tumors with microinvasion have a prognosis similar to that of the usual serous borderline tumor, and that conservation of the contralateral ovary and uterus may be acceptable therapy in young women who wish to preserve their fertility.

Entities:  

Mesh:

Year:  1990        PMID: 2318481     DOI: 10.1016/0046-8177(90)90201-f

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  8 in total

Review 1.  [Pitfalls and common problems in the differential diagnosis of epithelial ovarian tumors].

Authors:  S F Lax
Journal:  Pathologe       Date:  2019-02       Impact factor: 1.011

2.  Evaluation of microinvasion and lymph node involvement in ovarian serous borderline/atypical proliferative serous tumors: a morphologic and immunohistochemical analysis of 37 cases.

Authors:  Kruti P Maniar; Yihong Wang; Kala Visvanathan; Ie-Ming Shih; Robert J Kurman
Journal:  Am J Surg Pathol       Date:  2014-06       Impact factor: 6.394

Review 3.  Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.

Authors:  Murray Joseph Casey; Chhanda Bewtra
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

4.  Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes.

Authors:  Katherine Stemke-Hale; Kristy Shipman; Isidora Kitsou-Mylona; David G de Castro; Vicky Hird; Robert Brown; James Flanagan; Hani Gabra; Gordon B Mills; Roshan Agarwal; Mona El-Bahrawy
Journal:  Mod Pathol       Date:  2012-11-23       Impact factor: 7.842

Review 5.  Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria.

Authors:  Steffen Hauptmann; Katrin Friedrich; Raymond Redline; Stefanie Avril
Journal:  Virchows Arch       Date:  2016-12-27       Impact factor: 4.064

Review 6.  The Putative Role of TP53 Alterations and p53 Expression in Borderline Ovarian Tumors - Correlation with Clinicopathological Features and Prognosis: A Mini-Review.

Authors:  Andrzej Semczuk; Marek Gogacz; Anna Semczuk-Sikora; Maciej Jóźwik; Tomasz Rechberger
Journal:  J Cancer       Date:  2017-08-22       Impact factor: 4.207

7.  Proposal for Creating a Guideline for Cancer Registration of Microinvasive Tumors of the Breast and Ovary (II).

Authors:  Jin Hee Sohn; Gyungyub Gong; Kyu Rae Kim; Chang Suk Kang; Youn Soo Lee; Jin Man Kim; Woo Hee Jung; Kwang Sun Suh
Journal:  Korean J Pathol       Date:  2012-06-22

8.  Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors.

Authors:  Véronique Ouellet; Tak Hay Ling; Karine Normandin; Jason Madore; Christian Lussier; Véronique Barrès; Dimcho Bachvarov; Claudine Rancourt; Patricia N Tonin; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  BMC Cancer       Date:  2008-11-26       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.